Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 14/20 | 0.80 |
| ▸ | ICAM1 | P05362 | 14/20 | 0.80 |
| ▸ | ITGAL | P20701 | 14/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | FPR2 | P25090 | 1/20 | 0.63 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358036 | 1.00 | ITGB2 (0.80) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL200969 | 0.90 | ITGB2 (0.66) | ITGB2ICAM1ITGAL | |
| SCHEMBL30081478 | 0.88 | ITGB2 (0.74) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL16834384 | 0.88 | ITGB2 (0.74) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL11868630 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL12063160 | 0.86 | ITGB2 (0.71) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL15145360 | 0.86 | ITGB2 (0.74) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL11869604 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL11869919 | 0.86 | ITGB2 (0.80) | ITGB2ICAM1ITGALALDH1A1POLB | |
| SCHEMBL15780958 | 0.86 | ITGB2 (0.79) | ITGB2ICAM1ITGALALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | SARCODE BIOSCIENCE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2004-01-15 | — | — | US | disclosed |
| US-6673825-B2 | ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| EP-1339718-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | Bristol-Myers Squibb Company (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003029245-A1 | SPIRO-HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030013745-A1 | Urazole compounds useful as anti-inflammatory agents | CEREP SA (FR) | 2003-01-16 | — | — | US | disclosed |
| WO-2002094186-A2 | URAZOLE COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143692-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20040009998-A1 | Spiro-hydantoin compounds useful as anti-inflammatory agents | ICAM1, VCAM1, SELL | ITGB2 16/4885ICAM1 1/4885ITGAL 11/4885 |
| US-20170143693-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143691-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | ITGB2 4732/4885ICAM1 555/4885ITGAL 3218/4885 |
| US-20230233551-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20170143690-A1 | COMPOSITIONS AND METHODS FOR TREATMENT | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20030013745-A1 | Urazole compounds useful as anti-inflammatory agents | TPMT, IL4, IL5 | ITGB2 3006/4885ICAM1 863/4885ITGAL 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.